News

EQS-News: Uni-Bio Science Group Limited 2019 Annual Results Turnover Increased by 54.9% YoY to HK$209.4 million Recording EBITDA of HK$28.4 million Achieved Significant Progress towards Pipeline Product with 2 Product Launches Expected in 2020

EQS-News: Great Bay Bio injected with 2.5 million USD of convertible note

EQS-News: Great Bay Bio and Boji Medical have Reached Strategic Cooperation to Jointly Develop a Long-Acting Biological and Innovative Anti-Anemia Injection

Uni-Bio Science Group Announces 2023 Annual Results

 Marketing application of Diquafosol Sodium eye drops has been officially accepted by the China National Medical Products Administration (NMPA)

As A Breakthrough Drug For The Expansive Osteoporosis Market, Bogutai® (Teriparatide Injection) Has Been Officially Approved By The China National Medical Products Administration (NMPA)

Uni-Bio Science Group Limited Announces 2023 Interim Results

Uni-Bio Science Group Limited: 2022 Annual Results

Uni-Bio Science Group Limited: 2022 Interim Results

EQS-News: Marketing application of BOGUTAI® (teriparatide injection) has been officially accepted by the China National Medical Products Administration (NMPA)

EQS-News: Uni-Bio Science Group Limited：2021 Annual Results